Journal Article

Romiplostim for Treatment of Children and Young Adults With Severe Aplastic Anemia and Myelodysplastic Syndrome

Journal of Pediatric Hematology/Oncology (2024) 46(5) 252-261
DOI: 10.1097/MPH.0000000000002891
5Citations
Citations of this article
6Readers
Mendeley users who have this article in their library.
Get full text

Abstract

Thrombopoietin receptor agonists (TPO-RAs) induce trilineage hematopoiesis under conditions with acquired hematopoietic failure. We evaluated safety, tolerability, and preliminary efficacy of a TPO-RA, romiplostim (Nplate), with or without standard-of-care immunosuppressive therapy (± IST) for children (ages

Author supplied keywords

Cite

CITATION STYLE

APA

Sharathkumar, A., Carr, J., Claassen, D., Syrbu, S., Bhagavathi, S., Al-Huniti, A., … Mott, S. L. (2024). Romiplostim for Treatment of Children and Young Adults With Severe Aplastic Anemia and Myelodysplastic Syndrome. Journal of Pediatric Hematology/Oncology, 46(5), 252–261. https://doi.org/10.1097/MPH.0000000000002891

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free